JCB, Volume 9, Number 1, 2002 Editorial Vol.9 No. 1 (2002) Editorial: The future of plant biotechnology Jens A Katzek   Article Vol.9 No. 1 (2002) Biotechnology: The underutilised tool in the fight for global health and security Anne Sunderland Biotechnology companies can contribute to developing new treatments for diseases of thedeveloping world without losing money or converting to charity. Article Vol.9 No. 1 (2002) Reputation management in the biotechnology industry Robert W Grupp As biotechnology companies mature, the focus of their activities shifts from a research-and-development orientation to a business model based on marketed products that Article Vol.9 No. 1 (2002) EU regulation of genetically modified organisms: Food and feed, traceability and labelling Geraldine Schofield The European Commission has proposed two new regulations to deal with the labelling and traceability of genetically modified organisms (GMOs). These deal with both food Article Vol.9 No. 1 (2002) Transfer to Africa of the resources and rewards from biotechnology: The need for a participatory approach Belinda R. Clarke The low adoption rate of new technologies by rural communities in developing countries in the 1970s and 1980s revealed a need for a different approach to the setting of Article Vol.9 No. 1 (2002) Patentability of inventions involving human stem cells in Europe Philippe Bouvet In the last two years, research into stem cells has raised extraordinary therapeutic hopes – such as regenerative medicine – but also strong ethical quest Article Vol.9 No. 1 (2002) eClinical trials: The future is now Ronald G. Marks Clinical trial conduct today requires improvements in efficiency, accuracy and subject safety. These benefits are available as the industry makes clinical trial process Article Vol.9 No. 1 (2002) Delivering biotherapeutics – technical opportunities and strategic trends Simon Shohet As the list of biological drugs gaining regulatory approval grows, this paper examines how different technological approaches to delivering these drugs have evolved, an Article Vol.9 No. 1 (2002) Clinical trials in the pharmaceutical industry: The scope of the research exemption under French patent law – clarification is still awaited Marina Cousté This paper discusses a recent French Court decision and its impact on the judicial interpretation of the extent to which pharmaceutical clinical trials may or may not f Legal and Regulatory Updates Vol.9 No. 1 (2002) Legal and regulatory update John Wilkinson   Legal and Regulatory Updates Vol.9 No. 1 (2002) EU Financial accounts reports David Citron   Legal and Regulatory Updates Vol.9 No. 1 (2002) US Financial accounts reports Glenn Cocker   Book Review Vol.9 No. 1 (2002) Book Review Geraldine Schofield Market Development for Genetically Modified Foods V. Santaniello, R. E. Evenson and D. Zilberman (Eds) CABI Publishing, Wallingford; 2002; 336pp
